secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2021-07-27T23:59:59+00:00
Accession:  0001770787-21-000039
Event type: litigation
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics settles all patent litigation with Bio-Rad, enters global cross-license for single cell analysis
--------------------------------------------------------------------------------

- Cross license covers single cell analysis; excludes spatial, in situ, and digital PCR (for 10x).
- 10x to pay Bio-Rad $29.4M in royalties/interest for past GEM sales; $15.4M reversal in Q2 2021.
- Future royalty payments expected to impact gross margins by less than 1% through 2030.
- All outstanding litigation dismissed with prejudice.
- Agreement term is life of licensed patents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/0001770787-21-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078721000039/txg-20210726.htm
  HTML page:      https://secwatch.observer/filing/0001770787-21-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer